Arbor Pharmaceuticals Inc. is recalling 1,846 cartons of Nymalize (nimodipine) oral solution, 60 mg/20 mL, because the medication was found to be subpotent. This prescription drug, used to treat certain types of brain bleeding, contains less of the active ingredient than required. Affected products were distributed nationwide in the United States and include 12 unit-dose cups and 12 oral syringes per carton.
A subpotent drug may not provide the full intended dose, potentially leading to a lack of effectiveness in managing the patient's condition. While the risk level is classified as low, failing to receive the proper dosage of nimodipine could impact the treatment of serious medical conditions.
Healthcare provider consultation and pharmacy refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.